SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

Pre-Treatment Lymphopenia and NLR May Have Prognostic Value in Turkish High-Grade Glial Tumor Patients

Serkan GÖKÇAY
Ahmet Taner SÜMBÜL
Ahmet Murat SEDEF
Züleyha ÇALIKUŞU
Aykut BAHÇECİ
Pages
107–112
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Sixty-nine (62.2%) patients died and overall survival (OS)was estimated 28 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We aimed to determine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocytopenia in Turkish high-grade glial tumor patients.Methods: This study was designed as a hospital-based retrospective observational case series study.
📊
Key Findings & Data:A total of 111patients with recurrent glioblastoma multiforme (GBM) at four different oncology centers in Turkey between 2009 and2017 have included to our study.Results: All of the patients (n=111) had recurrent disease.
💡
Conclusion & Impact:Sixty-nine (62.2%) patients died and overall survival (OS)was estimated 28 months.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: We aimed to determine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocytopenia in Turkish high-grade glial tumor patients.Methods: This study was designed as a hospital-based retrospective observational case series study. A total of 111patients with recurrent glioblastoma multiforme (GBM) at four different oncology centers in Turkey between 2009 and2017 have included to our study.Results: All of the patients (n=111) had recurrent disease. Sixty-nine (62.2%) patients died and overall survival (OS)was estimated 28 months. Cutoff NLR value is found as 3.06. The OS of patients who had low NLR was statisticallysignificantly longer than the patients who had high NLR (30 months vs. 23 months, p=0.008). The OS of patients withlymphocytopenia was statistically significantly worse than the other group (24 months vs. 30 months, p=0.04). Progression-free survival was estimated 8 months. Median PFS was statistically better in GBM than the astrocytoma (8 monthsvs. 4 months, p=0.03).Conclusion: In our study, we showed that high NLR and lymphocytopenia may also have prognostic value in recurrentTurkish high-grade glial tumor patients and the present findings confirm that these markers may be used to predict themortality risks for these patients.

🔖

Cite This Article

GÖKÇAY, S., SÜMBÜL, A. T., SEDEF, A. M., ÇALIKUŞU, Z., BAHÇECİ, A. (2022). Pre-Treatment Lymphopenia and NLR May Have Prognostic Value in Turkish High-Grade Glial Tumor Patients. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 107–112. https://ajindex.com/articles/508595

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987– 96
  2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ,Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66
  3. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O’Fallon JR, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 2010;12:164–72
  4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9
  5. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5
  6. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi M, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb) 2011;21:264–75
  7. Wang PF, Song HW, Cai HQ, Kong LW, Yao K, Jiang T, et al. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival. Oncotarget 2017;8:50117– 23
  8. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 2013;114:149–54
  9. Kaya V, Yıldırım M, Yazıcı G, Yalçın AY, Orhan N, Güzel A. Prognostic significance of indicators of systemic inflammatory responses in glioblastoma patients. Asian Pac J Cancer Prev 2017;18:3287–91
  10. Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophilto-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 2015;15:617
  11. Lopes M, Carvalho B, Vaz R, Linhares P. Influence of neutrophillymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol 2018;136:173–80
  12. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572–8.